Management of New Onset Diplopia in Cerebral Venous Thrombosis

Clinical Presentation and Diagnosis

New onset diplopia in a patient with cerebral venous thrombosis should be recognized as a manifestation of increased intracranial pressure causing sixth nerve palsy, and the patient should receive immediate anticoagulation with either intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin, even if intracranial hemorrhage is present 1, 2
Diplopia in CVT typically results from sixth nerve palsy secondary to elevated intracranial pressure, not from direct thrombotic involvement of cranial nerves 3, 4, 5
The presence of diplopia indicates increased intracranial pressure exceeding 80% of cases with CVT, making this a critical warning sign requiring urgent intervention 3

Obtain MRI with MR venography immediately as the preferred diagnostic method 1, 2
Use CT venography if MRI is unavailable or contraindicated 1, 2
Consider catheter angiography only if high clinical suspicion persists despite negative initial imaging 1, 2

Start anticoagulation immediately upon diagnosis confirmation—this is non-negotiable even with hemorrhagic transformation 1, 2
Intravenous unfractionated heparin (dose-adjusted to aPTT 1.5-2.5× control) or subcutaneous low-molecular-weight heparin (body weight-adjusted dosing: typically enoxaparin 1 mg/kg twice daily) should be used for anticoagulation 1, 2
The presence of intracranial hemorrhage is explicitly NOT a contraindication to anticoagulation in CVT—this is a critical pitfall to avoid 1, 2

Admit to stroke unit or neurocritical care setting for close neurological monitoring every 2-4 hours 1, 2
Monitor specifically for signs of neurological deterioration, worsening headache, or decreased consciousness 2

Measure opening pressure if lumbar puncture is performed (typically >20 cmH2O, often >30 cmH2O in CVT) 3
Consider acetazolamide or serial lumbar punctures if intracranial pressure remains severely elevated despite anticoagulation 3
Treat seizures aggressively with antiepileptic medications if they occur (40% of CVT patients develop seizures) 3, 2

Transition to oral anticoagulation (warfarin with INR target 2-3 or direct oral anticoagulant) after initial heparin therapy (typically 5-10 days) 1, 2
Duration of anticoagulation depends on underlying etiology, with 3-6 months for transient/reversible risk factors, 6-12 months for unprovoked CVT or mild thrombophilia, and indefinite anticoagulation for severe thrombophilia or recurrent thrombosis 1, 2

Investigate underlying prothrombotic conditions, including complete blood count, factor V Leiden mutation, prothrombin G20210A mutation, antiphospholipid antibodies, protein C, protein S, antithrombin III deficiency, and screen for inflammatory conditions 3, 1, 2

Perform follow-up MR venography or CT venography at 3-6 months to assess recanalization in stable patients 1, 2
Earlier imaging (1-3 months) is indicated if symptoms persist or evolve despite treatment 2

Do not withhold anticoagulation due to fear of hemorrhagic complications—this is the most common error and worsens outcomes 1, 2
Do not confuse CVT-related diplopia with other causes of sixth nerve palsy—the key distinguishing feature is the presence of headache, papilledema, and elevated intracranial pressure 3, 4, 5
Do not delay anticoagulation for extensive thrombophilia workup—start treatment immediately and complete workup during hospitalization 3, 1